Skip to main content
TipRanks
Go Ultimate75% OFF

Celon Pharma SA (0RKX) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Celon Pharma SA has a market cap or net worth of PLN 843.18M. The enterprise value is PLN 1.14B.

Market Cap
PLN 843.18M
Enterprise Value
PLN 1.14B

Share Statistics

Celon Pharma SA has 53,911,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
53,911,500
Owned by Insiders
―
Owned by Institutions
0.22%

Financial Efficiency

Celon Pharma SA’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -14.09%.

Return on Equity (ROE)
-0.22
Return on Assets (ROA)
-0.17
Return on Invested Capital (ROIC)
-14.09%
Return on Capital Employed (ROCE)
-0.14
Revenue Per Employee
374.64K
Profits Per Employee
-141.72K
Employee Count
560
Asset Turnover
0.46
Inventory Turnover
9.55

Valuation Ratios

The current PE Ratio of Celon Pharma SA is 7.86. Celon Pharma SA’s PEG ratio is 0.02.

PE Ratio
7.86
PS Ratio
3.72
PB Ratio
1.67
Price to FCF
-10.14
Price to Operating Cash Flow
20.20
PEG Ratio
0.02

Income Statement

In the last 12 months, Celon Pharma SA had revenue of 209.80M and earned -79.36M in profits. Earnings per share was -1.47.

Revenue
209.80M
Gross Profit
-39.48M
Operating Income
-56.76M
Pretax Income
-58.97M
Net Income
-79.36M
EBITDA
-10.48M
Earnings Per Share (EPS)
-1.47

Cash Flow

In the last 12 months, operating cash flow was 41.21M and capital expenditures -123.26M, giving a free cash flow of -82.05M billion.

Operating Cash Flow
41.21M
Free Cash Flow
-82.05M
Free Cash Flow per Share
-1.52

Dividends & Yields

Celon Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-9.86%
Earnings Yield
12.45%

Stock Price Statistics

Beta
-0.22
52-Week Price Change
0.00%
50-Day Moving Average
22.50
200-Day Moving Average
22.50
Relative Strength Index (RSI)
―
Average Volume (3m)
―

Important Dates

Celon Pharma SA upcoming earnings date is Apr 28, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 18, 2026
Next Earnings Date
Apr 28, 2027
Ex-Dividend Date
―

Financial Position

Celon Pharma SA as a current ratio of 1.62, with Debt / Equity ratio of 5.21%

Current Ratio
1.62
Quick Ratio
1.20
Debt to Market Cap
0.00
Net Debt to EBITDA
0.04
Interest Coverage Ratio
-35.54

Taxes

In the past 12 months, Celon Pharma SA has paid 20.40M in taxes.

Income Tax
20.40M
Effective Tax Rate
-0.35

Enterprise Valuation

Celon Pharma SA EV to EBITDA ratio is 370.10, with an EV/FCF ratio of -11.75.

EV to Sales
4.31
EV to EBITDA
370.10
EV to Free Cash Flow
-11.75
EV to Operating Cash Flow
23.39

Balance Sheet

Celon Pharma SA has PLN 3.96M in cash and marketable securities with PLN 134.27M in debt, giving a net cash position of -PLN 130.31M billion.

Cash & Marketable Securities
PLN 3.96M
Total Debt
PLN 134.27M
Net Cash
-PLN 130.31M
Net Cash Per Share
-PLN 2.42
Tangible Book Value Per Share
PLN 9.09

Margins

Gross margin is -8.95%, with operating margin of -17.54%, and net profit margin of 46.29%.

Gross Margin
-8.95%
Operating Margin
-17.54%
Pretax Margin
63.84%
Net Profit Margin
46.29%
EBITDA Margin
1.16%
EBIT Margin
-17.54%